AR115416A1 - Moduladores de la expresión de apol1 - Google Patents

Moduladores de la expresión de apol1

Info

Publication number
AR115416A1
AR115416A1 ARP190101365A ARP190101365A AR115416A1 AR 115416 A1 AR115416 A1 AR 115416A1 AR P190101365 A ARP190101365 A AR P190101365A AR P190101365 A ARP190101365 A AR P190101365A AR 115416 A1 AR115416 A1 AR 115416A1
Authority
AR
Argentina
Prior art keywords
segment
modified oligonucleotide
linked nucleosides
cet
nucleoside
Prior art date
Application number
ARP190101365A
Other languages
English (en)
Inventor
Susan M Freier
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of AR115416A1 publication Critical patent/AR115416A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Las presentes realizaciones proporcionan métodos, compuestos y composiciones útiles para inhibir la expresión de APOL1, lo que puede ser útil para tratar, prevenir o mejorar una enfermedad asociada con APOL1. Reivindicación 1: Un compuesto que comprende un oligonucleótido modificado de 8 a 80 nucleósidos unidos de longitud que tiene una secuencia de bases nitrogenadas que comprende al menos 8, al menos 9, al menos 10, al menos 11 o al menos 12 bases nitrogenadas contiguas de cualquiera de las secuencias de bases nitrogenadas de las SEQ ID Nº 13 - 1941. Reivindicación 30: Un compuesto que consiste en un oligonucleótido modificado, en donde el oligonucleótido modificado tiene 16 nucleósidos unidos de longitud y consiste en la secuencia de SEQ ID Nº 1164, en donde el oligonucleótido modificado consta de un segmento gap constituido por nueve desoxinucleósidos unidos; un segmento lateral 5’ constituido por tres nucleósidos unidos; y un segmento lateral 3’ constituido por cuatro nucleósidos unidos; en donde el segmento gap está situado entre el segmento lateral 5’ y el segmento lateral 3’; en donde el segmento lateral 5’ consiste en nucleósidos cEt; en donde el segmento lateral 3’ consiste en un nucleósido cEt, un nucleósido cEt, un nucleósido cEt y un nucleósido 2’-O-metoxietilo en la dirección de 5’ a 3’; donde cada unión entre nucleósidos es una unión de tipo fosforotioato; y en donde cada citosina es una 5-metilcitosina.
ARP190101365A 2018-05-22 2019-05-22 Moduladores de la expresión de apol1 AR115416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862674865P 2018-05-22 2018-05-22

Publications (1)

Publication Number Publication Date
AR115416A1 true AR115416A1 (es) 2021-01-13

Family

ID=68613945

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101365A AR115416A1 (es) 2018-05-22 2019-05-22 Moduladores de la expresión de apol1

Country Status (24)

Country Link
US (3) US10927377B2 (es)
EP (1) EP3799570A4 (es)
JP (2) JP7247227B2 (es)
KR (1) KR20210011981A (es)
CN (3) CN112423792B (es)
AR (1) AR115416A1 (es)
AU (1) AU2019274461A1 (es)
BR (1) BR112020023436A2 (es)
CA (1) CA3099750A1 (es)
CL (1) CL2020003010A1 (es)
CO (1) CO2020015377A2 (es)
CR (1) CR20200631A (es)
EA (1) EA202092748A1 (es)
EC (1) ECSP20082339A (es)
IL (1) IL278785A (es)
JO (1) JOP20200291A1 (es)
MA (1) MA53924A (es)
MX (1) MX2020012497A (es)
NI (1) NI202000085A (es)
PE (1) PE20211397A1 (es)
PH (1) PH12020551995A1 (es)
SG (1) SG11202011397QA (es)
WO (1) WO2019226611A1 (es)
ZA (1) ZA202007537B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
MA53924A (fr) 2018-05-22 2021-08-25 Ionis Pharmaceuticals Inc Modulateurs de l'expression d'apol1
WO2023141432A2 (en) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2024040235A1 (en) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US9023355B2 (en) * 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
JP2015507924A (ja) * 2012-02-08 2015-03-16 アイシス ファーマシューティカルズ， インコーポレーテッド 第ｖｉｉ因子の発現を調節するための方法と組成物
US10130632B2 (en) * 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
EP2972381A2 (en) * 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
TW201718010A (zh) * 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
JP6877414B2 (ja) * 2015-09-24 2021-05-26 アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｋｒａｓ発現のモジュレーター
MA53924A (fr) 2018-05-22 2021-08-25 Ionis Pharmaceuticals Inc Modulateurs de l'expression d'apol1

Also Published As

Publication number Publication date
SG11202011397QA (en) 2020-12-30
CA3099750A1 (en) 2019-11-28
US10927377B2 (en) 2021-02-23
JOP20200291A1 (ar) 2020-11-15
MA53924A (fr) 2021-08-25
JP2021525084A (ja) 2021-09-24
ECSP20082339A (es) 2021-02-26
CN112423792B (zh) 2024-04-23
PH12020551995A1 (en) 2021-09-06
JP7247227B2 (ja) 2023-03-28
PE20211397A1 (es) 2021-07-27
EA202092748A1 (ru) 2021-04-19
WO2019226611A1 (en) 2019-11-28
IL278785A (en) 2021-01-31
CL2020003010A1 (es) 2021-06-11
US20190359981A1 (en) 2019-11-28
CN118127019A (zh) 2024-06-04
EP3799570A4 (en) 2022-04-27
TW202016305A (zh) 2020-05-01
ZA202007537B (en) 2021-09-29
MX2020012497A (es) 2021-02-15
CR20200631A (es) 2021-02-10
KR20210011981A (ko) 2021-02-02
JP2023075283A (ja) 2023-05-30
CO2020015377A2 (es) 2020-12-21
US11525136B2 (en) 2022-12-13
US20210079395A1 (en) 2021-03-18
BR112020023436A2 (pt) 2021-02-23
CN118127020A (zh) 2024-06-04
NI202000085A (es) 2021-03-11
AU2019274461A1 (en) 2021-01-14
EP3799570A1 (en) 2021-04-07
CN112423792A (zh) 2021-02-26
US20230265428A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
AR115416A1 (es) Moduladores de la expresión de apol1
AR113214A1 (es) Moduladores de la expresión de pcsk9
MX2023005326A (es) Composiciones de oligonucleótidos y métodos de las mismas.
PE20181267A1 (es) Modulacion de la expresion del virus de la hepatitis b (vhb)
CO6241169A2 (es) Metodos para el tratamiento de hipercolesterolemia
PE20190354A1 (es) Moduladores del factor del complemento b
PE20181085A1 (es) Composiciones y metodos para modular la expresion de angiotensinogeno
PE20191351A1 (es) Tratamiento aav de la enfermedad de huntington
CY1116876T1 (el) Ολιγονουκλεοτιδικα αναλογα που ενσωματωνουν 5-αζα-κυτοσινη σε αυτα
ES2539790T3 (es) Métodos y composiciones para modular c-met hiperestabilizado
PE20180800A1 (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
AR069821A1 (es) Composiciones y metodos de uso de la interferencia de arn para el control de nematodos
CO5601048A2 (es) Evento de algodon mon 88913 y composiciones y metodos para su deteccion
AR081993A1 (es) TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA SUBUNIDAD a REGULADA POR VOLTAJE DEL CANAL DE SODIO (SCNA) POR INHIBICION DEL TRANSCRIPTO ANTISENTIDO NATURAL DE SCNA
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
ATE496127T1 (de) Antisense-modulation der clusterinexpression
RU2019130898A (ru) Композиции для модуляции экспрессии атаксина 2
CO6251331A2 (es) Inhibicion de arni de expresion de alfa-enac
ES2383716T3 (es) Composiciones y métodos que utilizan ARN de interferencia de un gen del tipo OPR3 para el control de nemátodos
CU24574B1 (es) Oligonucleótido que contiene una secuencia nucleobase para disminuir la expresión de tau
AR081209A1 (es) Tratamiento de enfermedades relacionadas con la proteina 11 del tipo linfoma 2 de celulas b, (bcl2, bcl2l11) mediante la inhibicion del transcripto antisentido natural a bcl2l11
CL2023000394A1 (es) Análogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-il)arilsufonamida sustituidos como moduladores de la proteína cereblon
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
AR126957A1 (es) Compuestos y métodos para reducir la expresión de dmpk
ATE376445T1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid- analoge